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Abstract BACKGROUND: The clinical value of the diagnosis of metabolic syndrome (MS) 
in children and adolescents remains unclear. The aim of the present study was to 
assess the occurrence of metabolic complications, other than included in 2007 
IDF MS definition, in obese children and adolescents 
METHODS: The study included 75 (33 boys) obese adolescents (mean age 13.9 
years, mean BMI SDS 4.49). Classical (fasting glucose, TGL, HDL, blood pres-
sure) and non classical (insulin resistance [HOMA-IR], creatinine, AST, ALT, uric 
acid, fibrinogen, liver US and 24h BP profile) risk factors were compared between 
groups with and without MS. 15(8 boys) met the 2007 IDF criteria for MS. 
RESULTS: Patients with MS presented with significantly lower: BMI SDS (4.2 
vs. 5.8, p=0.02), mean 24h SBP (0.8 vs. 1.0, p=0.03), and uric acid level (352.1 
vs. 414.0, p=0.01). In both groups a significant percentage of abnormal results 
of 24hABPM (up to 42.9 and 57.6%), insulin resistance (85.7 % and 61.1%), non 
alcoholic fatty liver disease (57.4 % and 38.9 %) and hyperuricemia (69.2 % and 
55.3%) was observed. 
CONCLUSION: Recognizing the metabolic syndrome in adolescents does not 
provide any additional clinical benefits. It seems that in every obese child a wide, 
personalized diagnostic work-up should be performed.
Abbreaviations:
ABPM - ambulatory blood pressure monitoring,
ALT - alanine aminotransferase, 
AST - asparagines minotransferase,
BMI - body mass index, 
DBP  - diastolic blood pressure, 
dDBP  - mean day-time diastolic blood pressure, 
dSBP  - mean day-time systolic blood pressure, 
dMAP - mean day-time arterial pressure, 
eGFR - estimated glomerular filtration rate, 
HDL  - high density cholesterol, 
IDF  - International Diabetes Federation, 
MS  - metabolic syndrome, 
MAP  - mean arterial pressure, 
NAFLD  - non alcoholic fatty liver disease, 
nDBP  - mean night-time diastolic blood pressure, 
nSBP  - mean night-time systolic blood pressure, 
nMAP - mean night-time arterial pressure, 
TGL  - triglycerides, 
SBP - systolic blood pressure, 
SDS - standard deviation score
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INTRODUCTION
The growing prevalence of obesity in children and ado-
lescents has highlighted a need for the identification of 
young individuals at particular risk of metabolic com-
plications. For this purpose many attempts have been 
made to create definition of metabolic syndrome (MS) 
suitable for youths. Unfortunately proposed criteria 
have been mainly based on already existing definitions 
for adults adjusted for pediatric use (Zimmet et al. 
2007; Cook et al. 2003; Jolliffe&Janssen 2007; Pacifico 
et al. 2011; Tailor et al. 2010). Because the studies with 
hard clinical endpoints, such as morbidity and mortal-
ity, are still lacking, currently used cutoffs vary widely 
between definitions, and different definitions do not 
classify the same adolescents as having MS (Kelly et al. 
2011; Vanlancker et al. 2017). Moreover, the MS defi-
nitions include only selected biochemical parameters, 
that practically reflect only advanced, already existing, 
metabolic complications in adults. Such limitation of 
evaluated parameters does not include early markers 
of cardiovascular disorders, and therefore don’t allow 
the identification of young patients at risk of metabolic 
complications (Kelly et al. 2011; Vanlancker et al. 2017). 
Some authors point to the crucial role of many other 
than traditional MS parameters in the early recognition 
of metabolic disturbances and prevention of complica-
tions in obese adolescents. Abnormal circadian blood 
pressure rhythm, impaired glucose tolerance, hyper-
uricemia and hyperfibrinogenemia, non alcoholic fatty 
liver disease seem to be not less important than abnor-
mal results of ambulatory measurements of blood pres-
sure, elevated triglycerides, low HDL cholesterol nor 
elevated fasting glucose (Strojny et al. 2017; Mosca et al. 
2017; Lovely et al. 2013). Therefore to date, there is no 
clear consensus about the clinical value of the recogni-
tion of MS in children and adolescents on the basis of 
classical definitions (Vanlancker et al. 2017).
The aim of the study was to assess the occurrence of 
metabolic complications, other than included in 2007 
IDF MS definition, in obese children and adolescents.
MATERIAL
The study included 75 patients (33 boys), at the age of 
puberty (mean 13.9 years) with simple obesity (mean 
BMI SDS 4.49) (Table 1). The patients were recruited 
among patients referred for consultation to the Endo-
crine Department Outpatient Clinic in Children’s Uni-
versity Hospital in Krakow.
The aim of the study was to assess the occurrence of 
metabolic complications, other than included in 2007 
IDF MS definition, in obese children and adolescents.
METHODS
Body weight and height were measured to the nearest 
0.1 kg, and 0.1 cm using a stadiometer (Harpenden) and 
a balanced scale (Seca). Waist circumference was obtained 
at the midpoint between the lowest rib and the iliac. As 
the reference to calculate SDS for waist and hip circum-
ference, normal values for the local population were 
used. 24-hour BP monitoring was performed using an 
Ambulatory BP Monitor (Space labs 90217, USA), with 
a cuff which was the same size as the one used to measure 
casual blood pressure. Recordings with at least 70% valid 
readings and at least one reading every hour were con-
sidered for the analysis. The following parameters were 
analyzed: mean 24-h systolic (SBP), diastolic (DBP), and 
mean arterial pressure (MAP), mean day-time systolic 
(dSBP), diastolic (dDBP), and MAP (dMAP), mean 
night-time systolic (nSBP), diastolic (nDBP), and MAP 
(nMAP). Blood pressure load was calculated separately 
for the awake and asleep periods. BP load was defined 
as the percentage of valid BP measurements above a set 
threshold (95th percentile for sex and the height) value 
(Urbina et al. 2008; National High Blood Pressure Educa-
tion Program Working Group 2004). Loads in excess of 
30% were considered elevated. Loads in excess of 50% 
were considered severely elevated. The calculation of noc-
turnal dipping was based on a formula by the American 
Heart Association: [(dSBP– nSBP)/dSBP] × 100. Normal 
dipping was defined as a ≥10% decline in BP (Urbina et 
al. 2008; National High Blood Pressure Education Pro-
gram Working Group 2004). Standard oral glucose toler-
ance tests were performed with the assessment of fasting 
and postload glucose and insulin levels. HOMA-IR was 
calculated using the formula: [fasting insulin level (μIU/
mL) x fasting glucose level (mmol/L)]/22. The definition 
of insulin resistance was based on a HOMA-IR thresh-
old set for adolescents ( > 3.16) (Keskin et al. 2005). Uric 
acid (UA), aspargine aminotransferase (AST), alanine 
aminotransferase (ALT), glucose, triglycerides (TGL), 
high-density lipoprotein cholesterol (HDL) and creati-
nine concentrations were estimated in the fasting blood 
sample by the dry chemistry method with a Vitros 5.1.FF 
machine (Ortho-Clinical Diagnostics, Rochester, NY, 
USA). Estimated glomerular filtration rate (eGFR) was 
calculated by on-line calculator based on Schwartz and 
Counahan-Barratt Methods adjusted for pediatric popu-
lation ( http://nephron.com/bedside_peds_nic.cgi).
Ultrasonography was performed using Philips EnVi-
sor unit with an 3.5 MHz scanhead. Non alcoholic fatty 
liver disease was defined by the presence of surrogate 
markers: ALT levels (>35 IU/L) and increased echo-
genicity of the liver on ultrasound examination (Vajro et 
al. 2012).
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Tab. 1. Comparison of the selected, “non classical”  parameters in patients with and without MS.
Parameter Metabolic syndrome Non metabolic syndrome p-value
Age [years] 12.8 (2.47) 14.3 (2.19) 0.02*
BMI SDS 4.2 (1.41) 5.8 (2.86) 0.02*
24h SBP [SDS] 1.2 (0.99) 1.9 (1.08) 0.03*
24h DBP [SDS] 0.8 (0.72) 1.0 (0.62) 0.15
Night dip [%] 9.5 (5.29) 10.3 (5.96) 0.57
eGFR 114.6 (17.83) 109.3 (16.67) 0.38
Glucose 120’ post load [mmol/L] 5.9 (2.11) 6.3 (1.40) 0.11
Insulin 0’ (fasting) [μIU/mL] 20.9 (10.80) 24.6 (10.17) 0.11
Insulin 120’ post load [μIU/mL] 109.7 (61.14) 130.7 (53.52) 0.16
HOMAIR 4.2 (2.26) 4.9 (2.24) 0.11
AST [IU/L] 28.5 (8.58) 31.5 (13.19) 0.46
ALT [IU/L] 35.5 (17.69) 46.9 (35.49) 0.16
GGT [IU/L] 40.7 (38.72) 30.1 (23.71) 0.10
Uric acid [μmol/L] 352.1 (66.17) 414.0 (86.18) 0.01*
Fibrinogen [g/L] 3.8 (0.63) 3.6 (0.65) 0.39
Total cholesterol 4.4 (0.87) 4.7 (0.75) 0.19
LDL cholesterol 2.7 (0.78) 3.0 (0.82) 0.10
Notation used: mean (SD), *statistically significant values (p<0,05) 
STATISTICS
Categorical variables were expressed as counts and per-
centages. Empirical distribution of continuous variables 
was described using mean, standard deviation (notation 
used: mean [SD]). Statistical significance of differences 
between two independent groups was assessed using the 
Mann-Whitney test or chi-square test as appropriate. A 
p-value less than 0.05 was considered an indication of a 
statistically significant result. All statistical analyses were 
performed using Statistica 12 software (StatSoft Poland).
RESULTS
Among the study group only 15 (8 boys) met the 2007 
IDF criteria for MS. Surprisingly, they presented with 
significantly higher mean HDL level, lower TGL level, 
and lower mean DBP (Table 2). Patients that met cri-
teria for MS presented with significantly lower: BMI 
SDS, mean 24h SBP, and uric acid level. Patients in both 
groups (with MS, and who did not meet MS criteria) 
presented a significant percentage of abnormal results 
of 24h ABPM (up to 42.9 and 57.6%), and results of 
biochemical analysis. Insulin resistance assessed on 
the basis of HOMA-IR calculation with the cut-off 
value recommended for pubertal age was confirmed in 
85.7% patients with MS and 61.1 without MS. NAFLD 
and elevated UA were present in 57.4% and 69.2% of 
patients with MS respectively, and in 38.9% and 55.3% 
of non-MS participants. There were no significant dif-
ferences regarding frequency of that disorders in both 
groups (Table 3.).
Tables 1, 2 and 3 show the complete results of the 
present study.
DISCUSSION
The problem of obesity and its complications in chil-
dren and adolescents in 21st century is undoubted. The 
ongoing questions remain about how to diagnose these 
complications at the earliest possible stage, and what 
should be the best moment for therapeutic intervention. 
There is no doubt, that metabolic consequences of 
obesity are not only a problem of adulthood. In fact, 
risk factors of cardiovascular disease and type 2 dia-
betes are already present in children and adolescents 
(Cook et al. 2009). In early 2000s, it appeared that creat-
ing a definition of the MS for children and adolescents 
would identify individuals at the highest risk of devel-
oping complications, similarly to the adult population 
(Zimmet et al. 2007; Cook et al. 2003; Jolliffe&Janssen 
2007; Pacifico et al. 2011; Tailor et al. 2010). Metabolic 
syndrome has been defined as the clustering of risk fac-
tors for cardiovascular disease and type 2 diabetes mel-
litus, such as obesity, dyslipidemia, hypertension, and 
glucose intolerance. Creating the right definition, how-
ever, has been more difficult than expected. It seems, 
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that the underlying mechanisms leading to the develop-
ment of metabolic complications of obesity in adoles-
cence are different than in adults. However it is clear, 
that the cardinal feature is insulin resistance, there is a 
lack of clarity as to how insulin resistance in childhood 
is best assessed, in what clinical disorders it occurs, and 
whether it can be treated or prevented (Keskin et al. 
2005; Reaven 2013; Levy-Marchal et al. 2010). A factor 
that significantly impedes interpretation of the results 
of the research is that growth and puberty interfere 
with the variables used to define MS (Keskin et al. 2005; 
Brambilla et al. 2007). Therefore the cutoff values are 
difficult to set up. Due to the lack of the studies with 
hard clinical endpoints in this field, cutoffs vary widely 
between definitions, and different definitions do not 
classify the same adolescents as having MS. As a conse-
quence the prevalence of MS in adolescents varies a lot 
between studies. In a review, the prevalence in the gen-
eral population of adolescents ranged from 2.0 to 9.5% 
in USA and from 1.4 to 4.1% in Europe (using the IDF, 
WHO, and NCEP-ATP definition) (Tailor et al. 2010). 
The results of the present study show, that current defi-
nition of MS is not useful for the identification of the 
pediatric patients at the highest risk of cardiovascular 
or metabolic risk. Despite only 20% of participants met 
criteria of MS, most of them presented abnormal results 
of assessed parameters. Interestingly, even classical 
parameters, such as the mean values of TGL and HDL 
were significantly less favorable in patients without diag-
nosis of MS. The question remains whether it is actually 
valuable to diagnose MS in children and adolescents to 
start early with interventions ? The answer seems to be: 
no. Nevertheless the underlying mechanisms leading to 
these anthropometric, physiological, and biochemical 
abnormalities are incompletely understood. However it 
is clear, that the cardinal feature is insulin resistance, 
there is a lack of clarity as to how insulin resistance in 
childhood is best assessed, in what clinical disorders 
it occurs, and whether it can be treated or prevented 
(Reaven 2013; Levy-Marchal et al. 2010). The situation 
is even more complicated by recently published studies, 
that point to higher plasticity of cardiovascular system 
in the developmental period, in comparison to adults 
(Hochberg 2011; Tain & Joles 2015). This phenomenon 
is known as Developmental Plasticity or Programming 
since the genetic program adapts to existing environ-
mental conditions resulting in different phenotypes 
(Hochberg 2011). Therefore patients with prehyper-
tension and insulin resistance have an increased risk of 
complete hypertension, type 2 diabetes and cardiovas-
cular morbidity and mortality. On the other hand, early 
intervention, at the pre-clinical phase, can significantly 
improve prognosis. Hence, early detection of individu-
als that are at metabolic complications and early inter-
Tab. 2. Comparison of the classical parameters of the metabolic syndrome in patients with and without diagnosis of MS based on the 2007 
IDF definition. 
Parameter Metabolic syndrome Non metabolic syndrome p-value
Fasting glucose [mmol/L] 4.5 (0.37) 4.5 (0.32) 0.91
HDL [mmol/L] 1.17 (0.19) 0.8 (0.15) <0.001*
TGL [mmol/L] 1.3 (0.42) 2.5 (1.70) <0.001*
SBP [SDS] 1.2 (0.90) 0.8 (1.00) 0.03*
DBP [SDS] 0.8 (0.71) 1.0 (0.60) 0.02*
Notation used: mean (SD), *statistically significant values (p<0.05)
Tab. 3. Comparison of the selected, “classical” parameters in patients with and without MS.
Metabolic syndrome
[%]
Non metabolic syndrome
[%]
χ2 Pearsons p-value
24h MAP> 2 SDS 0 5.1 0.7 0.4
24h SBP load >30% 21.4 30.5 0.5 0.5
24h SBP load >50% 7.1 11.9 0.3 0.6
24h DBP load >30% 14.3 11.9 0.06 0.8
24h DBP load >50% 0 1.7 0.2 0.6
Night dip <10% 42.9 57.6 0.99 0.3
Low eGFR 7.1 3.4 0.4 0.5
HOMAIR >3.16 85.7 61.1 3.06 0.08
Hiperurycaemia 69.2 55.4 0.8 0.4
Non alcoholic fatty liver 
disease 57.4 38.9 1.5 0.2
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vention to reprogram metabolic complications may 
well allow us to reduce the future burden of childhood 
obesity (Starzyk et al. 2009). 
CONCLUSION
Recognizing the metabolic syndrome in children and 
adolescents does not provide any additional clinical 
benefits. It seems that in every child with obesity a wide, 
personalized diagnostic work-up should be performed, 
to allow intervention at the stage of preclinical changes.
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